Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text

Medicine, Cardiology, Preventive Medicine +16

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.8K citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine · 2008 · 7.4K citations · Full text

Medicine, Endocrinology, Internal Medicine +16